IP Library Granted Patent US 8,383,401
Granted Patent B2
US 8,383,401 · App. 13/167,414 · Granted Feb 26, 2013

T-cell receptor and nucleic acid encoding the receptor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,401
App. No.
13/167,414
Granted
Feb 26, 2013
Kind
B2
Abstract

A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4 143-151 -specific T cell receptor together with a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 2 of Sequence Listing.

Claims (30)

1. A recombinant cell transduced with a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:5 wherein expression of the nucleic acid results in production of a polypeptide that, when in combination with a polypeptide set forth in either of SEQ ID NO:2 or SEQ ID NO:7, is capable of forming a receptor that specifically binds to an HLA-A24-restricted, MAGE-A4 143-151 complex.

2. A recombinant cell wherein both of a first recombinant nucleic acid encoding a first polypeptide comprising the amino acid sequence of SEQ ID NO:5 and a second recombinant nucleic acid encoding a second polypeptide comprising the amino acid sequence of SEQ ID NO:7 are transduced into the cell resulting in expression of a HLA-A24-restricted, MAGE-A4 143-151 T cell receptor.

3. A recombinant cell transformed with a vector selected from the group consisting of:

(a) a vector comprising a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:5,

(b) a vector comprising a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 7,

(c) a vector comprising a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:5 and a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:7, and

(d) a combination of a vector comprising a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:5 and a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:7,

wherein expression of the nucleic acid or nucleic acids result in production of a polypeptide or polypeptides that are capable of forming a receptor that specifically binds to an HLA-A24-restricted, MAGE-A4 143-151 complex.

4. A recombinant T cell or cell capable of differentiating into a T cell transduced with a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:5 wherein expression of the nucleic acid results in production of a polypeptide that, when in combination with a polypeptide set forth in either SEQ ID NO:2 or SEQ DI NO:7, is capable of forming a receptor that specifically binds to an HLA-A24-restricted, MAGE-A4 143-151 complex.

5. A carcinostatic agent comprising, as an active ingredient, a recombinant cell transformed with a vector selected from the group consisting of:

(a) a vector comprising a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:5,

(b) a vector comprising a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 7,

(c) a vector comprising a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:5 and a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:7, and

(d) a combination of a vector comprising a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:5 and a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:7,

wherein expression of the nucleic acid or nucleic acids results in production of a polypeptide or polypeptides that are capable of forming a receptor that specifically binds an HLA-A24-restricted, MAGE-A4 143-151 complex.

6. A carcinostatic agent comprising a cell transduced with a first recombinant nucleic acid encoding a first polypeptide comprising the amino acid sequence of SEQ ID NO:5 and a second recombinant nucleic acid encoding a second polypeptide sequence comprising the amino acid sequence of SEQ ID NO: 7 wherein expression of the nucleic acids result in production of polypeptides that are capable of forming a receptor that specifically binds to an HLA-A24-restricted, MAGE-A4 143-151 complex.

7. A recombinant cell transduced with a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:7 wherein expression of the nucleic acid results in production of a polypeptide that, when in combination with a polypeptide set forth in either SEQ ID NO:2 or SEQ ID NO:7 is capable of forming a receptor that specifically binds to an HLA-A24-restricted, MAGE-A4 143-151 complex.

8. A recombinant T cell or cell capable of differentiating into a T cell transduced with a recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:7 wherein expression of the nucleic acid results in production of a polypeptide that, when in combination with a polypeptide set forth in either of SEQ ID NO:1 or SEQ ID NO:5, is capable of forming a receptor that specifically binds to an HLA-A24-restricted, MAGE-A4 143-151 complex.

9. The recombinant cell of claim 1 , wherein recombinant nucleic acid encoding the polypeptide comprises the amino acid sequence of SEQ ID NO:1.

10. The recombinant cell of claim 1 , wherein the nucleic acid encoding the polypeptide consists of the amino acid sequence of SEQ ID NO:5.

11. The recombinant cell of claim 2 , wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO:1 and wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:2.

12. The recombinant cell of claim 2 , wherein the first polypeptide consists of the amino acid sequence of SEQ ID NO:5 and wherein the second polypeptide consists of the amino acid sequence of SEQ ID NO:7.

13. The recombinant T cell or cell capable of differentiating into a T cell of claim 4 , wherein the recombinant nucleic acid encoding the polypeptide comprises SEQ ID NO:1.

14. The recombinant T cell or cell capable of differentiating into a T cell of claim 4 , wherein the recombinant nucleic acid encodes the polypeptide consisting of SEQ ID NO:5.

15. The carcinostatic agent comprising the cell of claim 6 , wherein the first recombinant nucleic acid encodes the polypeptide comprising the amino acid sequence of SEQ ID NO:1.

16. The carcinostatic agent comprising the cell of claim 6 , wherein the first recombinant nucleic acid encodes the polypeptide consisting of the amino acid sequence of SEQ ID NO:5.

17. The recombinant cell of claim 7 wherein the recombinant nucleic acid encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2.

18. The recombinant cell of claim 7 wherein the recombinant nucleic acid encodes a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:7.

19. The recombinant T cell or cell capable of differentiating into a T cell of claim 8 , wherein the recombinant nucleic acid encoding the polypeptide comprises SEQ ID NO:2.

20. The recombinant T cell or cell capable of differentiating into a T cell of claim 8 , wherein the recombinant nucleic acid encodes the polypeptide consisting of SEQ ID NO:7.

Assignments (1)
CHANGE OF ADDRESS Recorded Jun 24, 2016
From: TAKARA BIO INC.
To: TAKARA BIO INC.
Reel/Frame 039152/0834 →